Precision Biosciences, Inc.2024财年第三财季实现净利润-16.43百万美元，同比减少35.67%

市场透视11-10

11月10日，Precision Biosciences, Inc.（DTIL.US）公布财报，公告显示公司2024财年第三财季净利润为-16.43百万美元，同比减少35.67%；其中营业收入为576000.00美元，同比减少95.61%，每股基本收益为-2.25美元。从资产负债表来看，Precision Biosciences, Inc.（DTIL.US）总负债88.39百万美元，其中短期债务...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2482422161?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-10 00:02","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2482422161","market":"us","top_or_hot":-1,"title":"Precision Biosciences, Inc.2024财年第三财季实现净利润-16.43百万美元，同比减少35.67%","media":"市场透视","content":"<div>\n<p>11月10日，Precision Biosciences, Inc.（DTIL.US）公布财报，公告显示公司2024财年第三财季净利润为-16.43百万美元，同比减少35.67%；其中营业收入为576000.00美元，同比减少95.61%，每股基本收益为-2.25美元。从资产负债表来看，Precision Biosciences, Inc.（DTIL.US）总负债88.39百万美元，其中短期债务...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241110000239a227863f&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Precision Biosciences, Inc.2024财年第三财季实现净利润-16.43百万美元，同比减少35.67%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrecision Biosciences, Inc.2024财年第三财季实现净利润-16.43百万美元，同比减少35.67%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-10 00:02 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241110000239a227863f&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月10日，Precision Biosciences, Inc.（DTIL.US）公布财报，公告显示公司2024财年第三财季净利润为-16.43百万美元，同比减少35.67%；其中营业收入为576000.00美元，同比减少95.61%，每股基本收益为-2.25美元。从资产负债表来看，Precision Biosciences, Inc.（DTIL.US）总负债88.39百万美元，其中短期债务...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241110000239a227863f&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DTIL","symbol_name":"Precision Biosciences Inc","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241110000239a227863f&s=b","article_id":"2482422161","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241110000239a227863f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2482422161","pubTimestamp":1731168130,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月10日，Precision Biosciences, Inc.公布财报，公告显示公司2024财年第三财季净利润为-16.43百万美元，同比减少35.67%；其中营业收入为576000.00美元，同比减少95.61%，每股基本收益为-2.25美元。从资产负债表来看，Precision Biosciences, Inc.总负债88.39百万美元，其中短期债务1.28百万美元，资产负债比为0.02，流动比率为0.10。机构评级：截至2024年11月10日，当前有4家机构对Precision Biosciences, Inc.目标价做出预测，其中目标均价为35.75美元，其中最低目标价为19.00美元，最高目标价为60.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"DTIL":"Precision Biosciences Inc"},"translate_title":"Precision Biosciences, Inc. achieved net profit of-$16.43 million in the third fiscal quarter of fiscal 2024, a year-on-year decrease of 35.67%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DTIL":0.9},"content_text":"11月10日，Precision Biosciences, Inc.（DTIL.US）公布财报，公告显示公司2024财年第三财季净利润为-16.43百万美元，同比减少35.67%；其中营业收入为576000.00美元，同比减少95.61%，每股基本收益为-2.25美元。从资产负债表来看，Precision Biosciences, Inc.（DTIL.US）总负债88.39百万美元，其中短期债务1.28百万美元，资产负债比为0.02，流动比率为0.10。机构评级：截至2024年11月10日，当前有4家机构对Precision Biosciences, Inc.目标价做出预测，其中目标均价为35.75美元，其中最低目标价为19.00美元，最高目标价为60.00美元。公司简介：Precision BioSciences Inc 是一家基因组编辑公司，致力于通过其基因组编辑平台ARCUS改善生活。它利用ARCUS开发其候选产品，旨在治疗人类疾病并提供食品和农业解决方案。ARCUS的独特之处在于其相对较小的尺寸，这可能允许使用病毒和非病毒基因传递方法将其传递到更广泛的细胞和组织。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482422161"}